Searchable abstracts of presentations at key conferences in endocrinology

ea0083erco6 | Endocrine-related Cancer | EYES2022

Outcome of immuncheckpoint inhibitor therapy in adrenocortical carcinoma – A multicenter retrospective study

H Remde , L Schmidt-Pennington , M Reuter , L Landwehr , M Jensen , H Lahner , K Laubner , J Schreiner , J Bojunga , S Kircher , A Pohrt , M. V. Teleanu , D Hubschmann , A Stenzinger , H Glimm , S Frohling , M Fassnacht , K Mai , M. Kroiss

Background: Adrenocortical carcinoma is a rare endocrine malignancy with poor prognosis and few treatment options in advanced disease. Immune checkpoint inhibitors (ICI) have been studied in few clinical trials with a limited number of patients in ACC. No real-life data are available so far. In the present study we aimed at evaluating treatment response and safety of ICI treatment in advanced ACC and identifying clinical, biochemical, histological and molecular markers for pre...

ea0099rc3.6 | Rapid Communications 3: Adrenal and Cardiovascular Endocrinology | Part I | ECE2024

Mismatch repair deficiency and microsatellite instability in adrenocortical carcinoma: Diagnosis, prevalence, and clinical impact

Altieri Barbara , Herterich Sabine , Kircher Stefan , Jahn Arne , Teleanu Maria-Veronica , Lippert Juliane , Landwehr Laura-Sophie , Kimpel Otilia , Reuter Miriam , Remde Hanna , Stenzinger Albrecht , Glimm Hanno , Bargou Ralf , Froehling Stefan , Ronchi Cristina L , Appenzeller Silke , Fassnacht Martin , Matthias Kroiss

Background: DNA mismatch repair (MMR) maintains genomic integrity and stability. Inactivation of the MMR genes MLH1, PMS2, MSH2, and MSH6 by somatic or germline variants or gene methylation causes MMR deficiency (dMMR) leading to microsatellite instability (MSI) and high tumour mutational burden. In many tumour entities, patients with dMMR/MSI respond well to immune checkpoint inhibitor (ICI) therapy. The clinical relevance of dMMR and MSI i...